Correction to: SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion
Main Authors: | Sarah Halford, Susan Wan, Ilaria Dragoni, Julie Silvester, Bobojon Nazarov, Daniel Anthony, Suzie Anthony, Emma Ladds, John Norrie, Kevin Dhaliwal, and the CDD SPIKE-1 Project Team |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-04-01
|
Series: | Trials |
Online Access: | https://doi.org/10.1186/s13063-022-06266-0 |
Similar Items
-
SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion
by: Sarah Halford, et al.
Published: (2021-08-01) -
Inhibitory potentials of ivermectin, nafamostat, and camostat on spike protein and some nonstructural proteins of SARS-CoV-2: Virtual screening approach
by: Haruna Isiyaku Umar, et al.
Published: (2022-06-01) -
Spectral analysis of input spike trains by spike-timing-dependent plasticity.
by: Matthieu Gilson, et al.
Published: (2012-01-01) -
Spiked Helmet or Spiked Electrode?
by: Emre Aslanger, MD, et al.
Published: (2021-03-01) -
Spike to spike MT model and applications
by: Escobar Maria-Jose, et al.
Published: (2007-07-01)